| Name: | (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide |
| CAS Number: | 98319-26-7 |  3D/inchi
|
| FDA UNII: | 57GNO57U7G |
| Nikkaji Web: | J367.472J |
| Beilstein Number: | 4269024 |
| MDL: | MFCD00869737 |
| XlogP3: | 3.00 (est) |
| Molecular Weight: | 372.55232000 |
| Formula: | C23 H36 N2 O2 |
| BioActivity Summary: | listing |
| NMR Predictor: | Predict (works with chrome, Edge or firefox) |
Category:pharmaceuticals / chemical synthisis
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Assay: | 95.00 to 100.00
|
| Food Chemicals Codex Listed: | No |
| Melting Point: | 252.00 °C. @ 760.00 mm Hg
|
| Boiling Point: | 576.61 °C. @ 760.00 mm Hg (est)
|
| Flash Point: | 351.00 °F. TCC ( 177.40 °C. ) (est)
|
| logP (o/w): | 3.030 |
| Soluble in: |
| | water, 11.68 mg/L @ 25 °C (est) |
Organoleptic Properties:
| Odor and/or flavor descriptions from others (if found). |
Cosmetic Information:
Suppliers:
Safety Information:
| Preferred SDS: View |
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
oral-dog LD50 > 1000 mg/kg
GASTROINTESTINAL: NAUSEA OR VOMITING
Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 4091, 1994.
intraperitoneal-mouse LD50 372 mg/kg
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION
BEHAVIORAL: ATAXIA
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 4091, 1994.
oral-mouse LD50 486 mg/kg
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION
BEHAVIORAL: ATAXIA
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 4091, 1994.
intraperitoneal-rat LD50 885 mg/kg
GASTROINTESTINAL: PERITONITIS
GASTROINTESTINAL: ULCERATION OR BLEEDING FROM SMALL INTESTINE
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 4091, 1994.
oral-rat LD50 418 mg/kg
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION
GASTROINTESTINAL: ULCERATION OR BLEEDING FROM STOMACH
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 4091, 1994.
|
| Dermal Toxicity: |
subcutaneous-mouse LD50 > 2000 mg/kg
Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 4091, 1994.
subcutaneous-rat LD50 > 2000 mg/kg
SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"
Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 4091, 1994.
|
| Inhalation Toxicity: |
|
Not determined
|
Safety in Use Information:
| Category: | | pharmaceuticals / chemical synthisis |
| Recommendation for finasteride usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for finasteride flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
| EPI System: View |
| ClinicalTrials.gov:search |
| Daily Med:search |
| Chemical Carcinogenesis Research Information System:Search |
| AIDS Citations:Search |
| Cancer Citations:Search |
| Toxicology Citations:Search |
| Carcinogenic Potency Database:Search |
| EPA ACToR:Toxicology Data |
| EPA Substance Registry Services (SRS):Registry |
| Laboratory Chemical Safety Summary :57363 |
| National Institute of Allergy and Infectious Diseases:Data |
| WGK Germany:3 |
| (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide |
| Chemidplus:0098319267 |
| RTECS:CL5245000 for cas# 98319-26-7 |
References:
| | (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide |
| NIST Chemistry WebBook: | Search Inchi |
| Pubchem (cid): | 57363 |
| Pubchem (sid): | 135016317 |
Other Information:
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert- | butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide |
Articles:
| Info:Finasteride |
| PubMed:Role of GABA-active neurosteroids in the efficacy of metyrapone against cocaine addiction. |
| PubMed:The dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depression. |
| PubMed:Androgenetic alopecia (male pattern hair loss) in the United States: what treatments should primary care providers recommend? |
| PubMed:New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line. |
| PubMed:Effect of Phellius linteus water extract on benign prostatic hyperplasia. |
| PubMed:Male breast cancer and 5α-reductase inhibitors finasteride and dutasteride. |
| PubMed:Current status of 5α-reductase inhibitors in prostate disease management. |
| PubMed:Actos, slings, finasteride, and the vaccine compensation solution. |
| PubMed:Role of 5α-reductase inhibitors in androgen-stimulated skin disorders. |
| PubMed:Prevention strategies for prostate cancer. |
| PubMed:Prostate, baldness drugs linked to sexual dysfunction. |
| PubMed:[Prevention of uro-oncological diseases]. |
| PubMed:Fraction of macroporous resin from Smilax china L. inhibits testosterone propionate-induced prostatic hyperplasia in castrated rats. |
| PubMed:Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer. |
| PubMed:The effect of finasteride and dutasteride on the growth of WPE1-NA22 prostate cancer xenografts in nude mice. |
| PubMed:[Primary prevention of urologic tumors: prostate cancer]. |
| PubMed:5-α reductase inhibitors and prostate cancer prevention: where do we turn now? |
| PubMed:Effects of in utero exposure to D-004, a lipid extract from Roystonea regia fruits, in the male rat: a comparison with finasteride. |
| PubMed:The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. |
| PubMed:Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. |
| PubMed:Update on the pathogenesis, genetics and medical treatment of patterned hair loss. |
| PubMed:Types of hair loss and treatment options, including the novel low-level light therapy and its proposed mechanism. |
| PubMed:Selenium, but not lycopene or vitamin E, decreases growth of transplantable dunning R3327-H rat prostate tumors. |
| PubMed:Synergistic disruption of external male sex organ development by a mixture of four antiandrogens. |
| PubMed:An overview on 5alpha-reductase inhibitors. |
| PubMed:PCOS. |
| PubMed:Hypersensitivity to intravenous ondansetron: a case report. |
| PubMed:Preventing prostate cancer: new analyses put finasteride back on the map. |
| PubMed:Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. |
| PubMed:Anabolic effects of testosterone are preserved during inhibition of 5alpha-reductase. |
| PubMed:[Chemoprevention of prostate cancer. Current status]. |
| PubMed:Combinations of tomato and broccoli enhance antitumor activity in dunning r3327-h prostate adenocarcinomas. |
| PubMed:Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men. |
| PubMed:Psychological effect, pathophysiology, and management of androgenetic alopecia in men. |
| PubMed:Preventing diseases of the prostate in the elderly using hormones and nutriceuticals. |
| PubMed:Clinical trials in cancer prevention: current results and perspectives for the future. |
| PubMed:Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia. |
| PubMed:Common hair loss disorders. |
| PubMed:The potential role of minoxidil in the hair transplantation setting. |
| PubMed:Dietary supplement use in the Prostate Cancer Prevention Trial: implications for prevention trials. |
| PubMed:Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents. |
| PubMed:Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations. |
| PubMed:Bioequivalence study of finasteride. Determination in human plasma by high-pressure liquid chromatography coupled to tandem mass spectrometry. |
| PubMed:Continuous haemodynamic monitoring in an unusual case of swallow induced syncope. |
| PubMed:Planning and analysis of repeated measures at key time-points in clinical trials sponsored by pharmaceutical companies. |
| PubMed:Study of the Food and Drug Administration files on Propecia: dosages, side effects, and recommendations. |
| PubMed:Gone today, hair tomorrow? |
| PubMed:Clinical pharmacokinetics and pharmacodynamics of finasteride. |
| PubMed:[Chemoprevention of cancer of the prostate]. |
| PubMed:New drugs from 1991-1992. |
| PubMed:From the Food and Drug Administration. |
|
an orally active 3-oxo-5-alpha-steroid 4-dehydrogenase inhibitor. it is used as a surgical alternative for treatment of benign prostatic hyperplasia. Finasteride is an androgen antagonist. Finasteride is one of the currently available pharmacologic treatment modalities with proven efficacy for treatment of androgenetic alopecia. Androgenetic alopecia (AGA), or male pattern hair loss, affects approximately 50% of the male population. AGA is an androgen-related condition in genetically predisposed individuals. There is no treatment to completely reverse AGA in advanced stages, but with medical treatment (e.g., finasteride), the progression can be arrested and partly reversed in the majority of patients who have mild to moderate AGA. Finasteride may increase the sensitivity of prostate specific antigen to detect prostate cancer. At present, finasteride remains the only intervention shown in long-term prospective phase III clinical trials to reduce the incidence of prostate cancer. (PMID: 18044109, 17543725, 17414641, 17415094, 17394699) [HMDB]
|
